ArticleTranslational vision science & technology2026
Explicit Inclusion of Diabetes Mellitus Without Retinopathy Within Diabetic Retinopathy Prediction.
Article in Translational vision science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The purpose of this study was to evaluate whether explicitly modeling diabetes mellitus (DM) without diabetic retinopathy (DR) as its own stage enables deep learning (DL) to detect early retinal changes for early risk identification of DR severity spectrum. Methods: We developed 3 DL classification models that explicitly incorporated DM without DR as a distinct stage using 3-class, 4-class, and 6-class staging granularity using 6069 color fundus images from the University of Illinois Chicago Hospital, including 1996 no-DM cases, 1852 DM without DR cases, and 2221 DR cases (516 mild, 220 moderate, 103 severe, and 1382 proliferative DR [PDR]). We developed segmentation models for the optic nerve head (ONH) and retinal vessels to quantify the impact of these regions on classification performance through targeted perturbations. We also examined spatial changes in retinal features across DR stages by measuring the alignment between DL saliency maps and ONH location. Results: For the 3-class model, areas under the curve (AUCs) were 92.2% (no-DM), 80.3% (DM without DR), and 74.1% (mild DR). For the 4-class model, AUCs were 94.0% (no-DM), 71.9% (DM without DR), 61.5% (mild DR), and 80.3% (referable DR). For the 6-class model, AUCs were 94.0% (no-DM), 65.7% (DM without DR), 65.6% (mild DR), 58.9% (moderate DR), 58.6% (severe DR), and 76.1% (PDR). Vessel perturbations reduced performance by 16% to 31% across models, and greater DR severity was associated with increased saliency-to-ONH distances (Pearson r = 0.69-0.72, P < 0.001). Conclusions: Explicitly modeling diabetes without retinopathy improved early-stage discrimination and revealed feature-reliance shifts with DR severity. Vessel- and saliency-based analyses identified subtle retinal changes preceding clinical DR. Translational Relevance: Treating diabetes without retinopathy as its own stage may enhance early DR risk identification and aid development of clinically useful artificial intelligence (AI) tools.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.